- Home
- CPRX
as of 12-10-2025 11:34am EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.9B | IPO Year: | 2006 |
| Target Price: | $32.60 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.71 | EPS Growth: | 44.94 |
| 52 Week Low/High: | $19.05 - $26.58 | Next Earning Date: | 11-05-2025 |
| Revenue: | $578,196,000 | Revenue Growth: | 25.56% |
| Revenue Growth (this year): | 19.87% | Revenue Growth (next year): | 7.21% |
AI-Powered CPRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
Chief Compliance/Legal Officer
Avg Cost/Share
$22.70
Shares
40,000
Total Value
$908,000.00
Owned After
231,039
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Nov 12, 2025 | Sell | $22.70 | 40,000 | $908,000.00 | 231,039 |
Compare CPRX vs Leading Stocks
See how CPRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.